Replimune Group Inc
NASDAQ:REPL
Replimune Group Inc
Total Receivables
Replimune Group Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Replimune Group Inc
NASDAQ:REPL
|
Total Receivables
$3m
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$12.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$9.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Total Receivables
$17.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$2.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
28%
|
|
Replimune Group Inc
Glance View
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
See Also
What is Replimune Group Inc's Total Receivables?
Total Receivables
3m
USD
Based on the financial report for Dec 31, 2025, Replimune Group Inc's Total Receivables amounts to 3m USD.
What is Replimune Group Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
7%
Over the last year, the Total Receivables growth was -4%. The average annual Total Receivables growth rates for Replimune Group Inc have been 14% over the past three years , 7% over the past five years .
